GV returned to help heart disease drug developer Tenaya boost its overall funding to approximately $248m.
Month: March 2021
Connect Bio to attach itself to public markets
Eli Lilly-backed inflammatory disease drug developer has filed to raise up to $100m in an initial public offering in the United States.
Oxular eyes $37m round
Hovione Scientia and Consort Medical-backed Oxular has secured funding that will support phase 2 trials for a treatment for diabetic macular oedema.
Cision to snag Brandwatch in $450m acquisition
Cision, already a shareholder in the social media analytics provider, is set to pay $450m to acquire it, following $63m in funding.
Carisma charms its way to $59m
Penn Medicine contributed to a $12m extension for the cancer immunotherapy developer’s series B round, which already inlcuded Livzon, Merck & Co and AbbVie.
MDLive heads to Evernorth
Sutter Health, Novo, Sentara and Health Care Service Corporation are set to exit the virtual healthcare provider in an acquisition of undisclosed size.
CorPower uncorks new funding
Midroc Europe led a round that increzased the wave energy technology developer’s total equity funding to $25m.
Rokk3r acquires AdMobilize
Axel Springer has exited the advertising data technology provider, which has been bought by Rokk3r together with its Matrix Labs spinoff for $19.5m.
Armorblox stocks up with $30m
Siemens’ Next47 unit led a series B round for the email security platform developer, increasing its total funding to more than $46m.
PharmEasy sells stake to CDPQ
The pension fund will pay an undisclosed sum for a 2% stake in API Holdings, the owner of online drugstore PharmEasy backed by Ascent Health and Medi Assist.
Manbang Group loads up billion-dollar IPO
Tencent, SoftBank and Alphabet are in line for exits after the trucking services provider confidentially filed to float in a US initial public offering sized above $1bn.
Legend Capital unveils 10-figure renminbi fund
Xiangcheng Financial Holdings is among the backers for the first close of the Legend Holdings spinoff’s sixth renminbi-denominated vehicle.
AstraZeneca achieves Moderna stake sale
AstraZeneca likely received over $1bn from selling its shares, having invested $140m in the publicly listed covid-19 vaccine developer in 2015.
Skydio soars with $170m
Siemens’ Next47 subsidiary has returned to back the unmanned aerial vehicle technology producer’s latest round, valuing it above $1bn.